<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:37:30Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/33412" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/33412</identifier><datestamp>2026-07-24T07:07:37Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Ashkar, Ali</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Moinuddin, Adnan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department">Medical Sciences (Molecular Virology and Immunology Program)</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2026-07-23T17:11:16Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2026</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/11375/33412</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/1077</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Natural killer (NK) cells are a promising approach for cancer immunotherapy. Current evidence from the clinic suggests that NK cells are a safe form of immunotherapy and have demonstrated the ability to improve patient prognosis in hematological malignancies. However, NK cells and immunotherapy overall have delivered modest results against solid tumors. The dampening of NK cell function against solid tumors has been attributed to the immunosuppressive and metabolically hostile tumor microenvironment. To address these limitations, NK cells have been co-cultured with feeder cells expressing membrane-bound IL-21 (mbIL-21). NK cells cultured using this method demonstrate greater proliferation, telomere lengthening, and metabolic reprogramming. However, ex vivo culturing methods have not been rigorously tested in the clinic. Further, evidence from preclinical models suggests that ex vivo-expanded NK cells may not persist long enough to achieve tumor clearance. This has led us to investigate an in vivo-directed approach in which NK cells can be expanded within the body. Further, such an approach could be combined with an ex vivo approach to enhance anti-tumor responses. Here, we utilized multiple approaches, including DNA aptamers, peptides, protein engineering, and protein design, to assess whether NK cell function can be enhanced. Through our protein engineering and protein design approaches, we also demonstrated enhanced tumor control and NK cell proliferation. Our results provide a proof of concept for enhancing NK cell function through different approaches, with varying degrees of success. Taken together, these findings highlight how NK cell therapy can also benefit from in vivo directed approaches.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject">NK cells</dim:field>
   <dim:field mdschema="dc" element="subject">cancer immunotherapy</dim:field>
   <dim:field mdschema="dc" element="subject">solid tumors</dim:field>
   <dim:field mdschema="dc" element="title">Strategies for Enhancing the Function of Natural Killer Cells In Vivo Against Hard-To-Treat Solid Tumors</dim:field>
   <dim:field mdschema="dc" element="type" lang="en">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>